blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1500400

EP1500400 - DRUG CONTAINING ANTIBODY COMPOSITION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  22.08.2008
Database last updated on 28.09.2024
Most recent event   Tooltip22.08.2008Application deemed to be withdrawnpublished on 24.09.2008  [2008/39]
Applicant(s)For all designated states
KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohtemachi 1-chome Chiyoda-ku
Tokyo 100-8185 / JP
[N/P]
Former [2005/04]For all designated states
KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohtemachi 1-chome
Chiyoda-ku, Tokyo 100-8185 / JP
Inventor(s)01 / NIWA, Rinpei, c/o Kyowa Hakko Kogyo Co., Ltd.
6-6, Asahimachi 3-chome
Machida-shi, Tokyo 194-8533 / JP
02 / SHITARA, Kenya, c/o Kyowa Hakko Kogyo Co., Ltd.
6-6, Asahimachi 3-chome
Machida-shi, Tokyo 194-8533 / JP
 [2005/04]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[N/P]
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2005/04]VOSSIUS & PARTNER
Siebertstrasse 4
81675 München / DE
Application number, filing date03723097.609.04.2003
[2005/04]
WO2003JP04503
Priority number, dateJP2002010694909.04.2002         Original published format: JP 2002106949
[2005/04]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03084569
Date:16.10.2003
Language:EN
[2003/42]
Type: A1 Application with search report 
No.:EP1500400
Date:26.01.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 16.10.2003 takes the place of the publication of the European patent application.
[2005/04]
Search report(s)International search report - published on:JP16.10.2003
(Supplementary) European search report - dispatched on:EP11.09.2006
ClassificationIPC:A61K39/395, A61P9/00, A61P29/00, A61P31/04, A61P31/12, A61P31/14, A61P35/00, A61P37/02, A61P37/04, A61P37/08, A61P43/00, C12P21/08, C12N15/09, C12N5/10, C07K16/18
[2006/41]
CPC:
C07K16/2896 (EP,US); A61P29/00 (EP); A61P31/04 (EP);
A61P31/12 (EP); A61P31/14 (EP); A61P35/00 (EP);
A61P37/02 (EP); A61P37/04 (EP); A61P37/08 (EP);
A61P43/00 (EP); A61P9/00 (EP); C07K16/18 (EP,US);
C07K16/2866 (EP,US); C07K16/44 (EP,US); C07K2317/41 (EP,US);
C07K2317/732 (EP,US) (-)
Former IPC [2005/04]A61K39/395, A61P9/00, A61P29/00, A61P31/04, A61P31/12, A61P31/14, A61P35/00, A61P37/02, A61P37/04, A61P37/08, A61P43/00, G01N33/15, // (C12P21/08, C12N15:09, 5:10, C07K16:18), C12P21:08, C12R1:91, C12N5:10, C12R1:91
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/04]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:ARZNEIMITTEL MIT ANTIKÖRPER-ZUSAMMENSETZUNG[2005/04]
English:DRUG CONTAINING ANTIBODY COMPOSITION[2005/04]
French:MEDICAMENT CONTENANT UNE COMPOSITION ANTICORPS[2005/04]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase09.11.2004Translation filed 
09.11.2004National basic fee paid 
09.11.2004Search fee paid 
09.11.2004Designation fee(s) paid 
09.11.2004Examination fee paid 
Examination procedure25.09.2003Request for preliminary examination filed
International Preliminary Examining Authority: JP
09.11.2004Examination requested  [2005/04]
29.08.2007Despatch of a communication from the examining division (Time limit: M06)
11.03.2008Application deemed to be withdrawn, date of legal effect  [2008/39]
09.05.2008Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2008/39]
Fees paidRenewal fee
02.05.2005Renewal fee patent year 03
30.03.2006Renewal fee patent year 04
27.04.2007Renewal fee patent year 05
20.03.2008Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO9954342  (UMANA PABLO [CH], et al) [X] 1-21 * page 11, line 9 - line 10 * * page 20, line 25 - page 25, line 11 * * example 3 * * claims 1,2,4,6,32-38,74-83 *;
 [E]WO03035835  (GENENTECH INC [US]) [E] 1-19 * page 10, paragraph L - page 12, paragraph 4 * * page 16, paragraph 6 - page 35, paragraph 3 * * page 41, paragraph 1 - page 43, paragraph 4 * * page 52, paragraph 2 - page 54, paragraph 3 * * example 1 * * claims 1-24,32-35 *;
 [L]WO03085107  (KYOWA HAKKO KOGYO KK [JP], et al) [L] * the whole document *;
 [L]WO03085119  (KYOWA HAKKO KOGYO KK [JP], et al) [L] * the whole document *;
 [L]WO03085102  (KYOWA HAKKO KOGYO KK [JP], et al) [L] * the whole document *;
 [L]WO03085118  (KYOWA HAKKO KOGYO KK [JP], et al) [L] * the whole document *;
 [E]EP1498485  (KYOWA HAKKO KOGYO KK [JP]) [E] 1-21 * the whole document *;
 [E]EP1498491  (KYOWA HAKKO KOGYO KK [JP]) [E] 1-21 * the whole document *;
 [E]EP1498490  (KYOWA HAKKO KOGYO KK [JP]) [E] 1-21 * the whole document *;
 [E]EP1500698  (KYOWA HAKKO KOGYO KK [JP]) [E] 1-21 * the whole document *;
 [A]  - LIFELY M R (REPRINT) ET AL, "Glycosylation and biological-activity of CAMPATH-1H expressed in different cell-lines and grown under different culture conditions", GLYCOBIOLOGY, IRL PRESS,, GB, (199512), vol. 5, no. 8, ISSN 0959-6658, pages 813 - 822, XP002096118 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1093/glycob/5.8.813
 [A]  - CLARK M R, "IGG EFFECTOR MECHANISMS", CHEMICAL IMMUNOLOGY, (1997), vol. 65, pages 88 - 110, XP001204090 [A] 1-21 * the whole document *
 [A]  - GRABENHORST E ET AL, "GENETIC ENGINEERING OF RECOMBINANT GLYCOPROTEINS AND THE GLYCOSYLATION PATHWAY IN MAMMALIAN HOST CELLS", GLYCOCONJUGATE JOURNAL, LUND, SE, (199902), vol. 16, no. 2, ISSN 0282-0080, pages 81 - 97, XP008005300 [A] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1023/A:1026466408042
International search[A]WO9727303  (TOYO BOSEKI [JP], et al);
 [X]WO0061739  (KYOWA HAKKO KOGYO KK [JP], et al);
 [XP]WO0231140  (KYOWA HAKKO KOGYO KK [JP]);
 [A]  - RIPKA J. ET AL., "Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose", ARCH. BIOCHEM. BIOPHYS., (1986), vol. 249, no. 2, pages 533 - 545, XP002971006

DOI:   http://dx.doi.org/10.1016/0003-9861(86)90031-7
 [X]  - SHITARA K. ET AL., "A new vector for the high level expression of chimeric antibodies in myeloma cells", J. IMMUNOL. METHODS, (1994), vol. 167, no. 1-2, pages 271 - 278, XP002911931

DOI:   http://dx.doi.org/10.1016/0022-1759(94)90096-5
 [A]  - DAVIES J. ET AL., "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for Fc gamma RIII", BIOTECHNOL. BIOENG., (2001), vol. 74, no. 4, pages 288 - 294, XP002964541

DOI:   http://dx.doi.org/10.1002/bit.1119
 [A]  - HACKETT J. JR. ET AL., "Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to toxoplasma gondii", J. CLIN. MICROBIOL., (1998), vol. 36, no. 5, pages 1277 - 1284, XP002971007
 [A]  - ELBASHIR S.M. ET AL., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, (2001), vol. 411, no. 6836, pages 494 - 498, XP002206451

DOI:   http://dx.doi.org/10.1038/35078107
 [A]  - SHIELDS R.L. ET AL., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improced binding to the Fc gamma R", J. BIOL. CHEM., (2001), vol. 276, no. 9, pages 6591 - 6604, XP002971008

DOI:   http://dx.doi.org/10.1074/jbc.M009483200
 [XP]  - SHIELDS R.L. ET AL., "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-.dependent cellular toxocity", J. BIOL. CHEM., (200207), vol. 277, no. 30, pages 26733 - 26740, XP002964542

DOI:   http://dx.doi.org/10.1074/jbc.M202069200
 [XP]  - SHINKAWA T. ET AL., "The absence of fucose but not the presence of galkactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", J. BIOL. CHEM., (2003), vol. 278, no. 5, pages 3466 - 3473, XP002965857

DOI:   http://dx.doi.org/10.1074/jbc.M210665200
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.